About the Project

In Scotland, 1 in 20 people live with diabetes, most of whom have type 2 diabetes. This condition significantly increases the risk of serious health complications like heart disease, stroke, and chronic kidney disease. While certain medications used in the management of diabetes are proven to reduce these risks, they may not currently be prescribed to all eligible patients. 

PRESIDE is a primary care project aimed at identifying the highest-risk type 2 diabetes patients across NHS Greater Glasgow & Clyde and optimising their medication regimen to help prevent cardiovascular and kidney disease. Using West of Scotland Safe Haven data, the project automatically calculates each patient’s 10-year risk of developing cardiovascular disease. 

Patients identified as high-risk are contacted by a specially formed NHS prescribing peripatetic pharmacy team, who conduct medication review appointments to optimise treatment and reduce future health risks. If appropriate, medication adjustments are made in agreement with the patient.

How DHVL Supported this Project

The Digital Health Validation Lab played a key role in shaping the PRESIDE project by leading Patient and Public Involvement and Engagement (PPIE) efforts. This engagement ensured that the project’s peripatetic and clinical models were designed with patient needs in mind, making care more accessible, effective, and patient-centred.

Alongside DHVL, the West of Scotland Innovation Hub has been instrumental by listening to and supporting the needs of primary care colleagues to develop an innovative peripatetic team solution for therapy optimisation. This strategic alignment aims to bring about positive change in patient prescribing practices, particularly within an overwhelmed healthcare system.

The Team

GB-66654   Date of Preparation May 25